Evelo Biosciences Overview
- Year Founded
-
2014
- Status
-
Out of Business
- Employees
-
66
- Latest Deal Type
-
Liquidation
Evelo Biosciences General Information
Description
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Contact Information
Website
www.evelobio.comCorporate Office
- 620 Memorial Drive
- Cambridge, MA 02139
- United States
Corporate Office
- 620 Memorial Drive
- Cambridge, MA 02139
- United States
Evelo Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Bankruptcy: Liquidation | 20-Nov-2023 | Completed | Bankruptcy: Liquidation | |||
| 9. Debt Refinancing | 01-Oct-2023 | Completed | Generating Revenue | |||
| 8. PIPE | 11-Jul-2023 | Completed | Generating Revenue | |||
| 7. PIPE | 02-Feb-2021 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 5. IPO | 08-May-2018 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 23-Mar-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 17-Jan-2017 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 16-Jun-2016 | $16.6M | $30.7M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 04-Nov-2015 | $14M | $14M | Completed | Startup |
Evelo Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | 10,164,552 | $0.001000 | 8% | $0.6 | $0.6 | 1x | $0.6 | 8.18% |
| Series A | 13,470,279 | $0.001000 | 8% | $0.6 | $0.6 | 1x | $0.6 | 10.84% |
Evelo Biosciences Comparisons
Industry
Financing
Details
Evelo Biosciences Competitors (123)
One of Evelo Biosciences’s 123 competitors is Seres Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
| Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Evelo Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Evelo Biosciences Patents
Evelo Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250127823-A1 | Compositions and methods of affecting cytokine levels using prevotella histicola | Pending | 07-Feb-2022 | ||
| EP-4404921-A1 | Solid dosage forms containing bacteria and microbial extracellular vesicles | Pending | 24-Sep-2021 | ||
| US-20250114411-A1 | Solid dosage forms containing bacteria and microbial extracellular vesicles | Pending | 24-Sep-2021 | ||
| EP-4319723-A1 | Pharmaceutical composition containing bacteria | Inactive | 08-Apr-2021 | ||
| US-20250073285-A1 | Pharmaceutical composition containing bacteria | Pending | 08-Apr-2021 | A61K35/747 |
Evelo Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Evelo Biosciences Acquisitions (1)
Evelo Biosciences’s most recent deal was a Merger/Acquisition with Epiva Biosciences. The deal was made on 12-Jul-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Epiva Biosciences | 12-Jul-2016 | Merger/Acquisition | Biotechnology |
Evelo Biosciences ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
35.17 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Evelo Biosciences FAQs
-
When was Evelo Biosciences founded?
Evelo Biosciences was founded in 2014.
-
Where is Evelo Biosciences headquartered?
Evelo Biosciences is headquartered in Cambridge, MA.
-
What is the size of Evelo Biosciences?
Evelo Biosciences has 66 total employees.
-
What industry is Evelo Biosciences in?
Evelo Biosciences’s primary industry is Biotechnology.
-
Is Evelo Biosciences a private or public company?
Evelo Biosciences is a Private company.
-
What is Evelo Biosciences’s current revenue?
The current revenue for Evelo Biosciences is .
-
How much funding has Evelo Biosciences raised over time?
Evelo Biosciences has raised $306M.
-
Who are Evelo Biosciences’s competitors?
Seres Therapeutics, NovaBiotics, Light Chain Bioscience, Innovimmune Biotherapeutics, and Inovio Pharmaceuticals are some of the 123 competitors of Evelo Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
